Standard regimens combine proteasome inhibitors, alkylating agents, immunotherapies, immunomodulators, and corticosteroids
Consider how much ongoing contact you want with your healthcare provider
The advantage
Originally FDA-approved as Ozempic for type 2 diabetes in 2017, semaglutide was subsequently approved as Wegovy for chronic weight management in 2021 making it one of the most rigorously studied weight loss medications ever approved
doi: 10.1016/j.geoderma.2018.12.027 84 RicachenevskyF
Eli Lilly published the results of its ATTAIN-1b trial for obesity in September 2025 7 , which compared orforglipron to placebo in more than 3,100 adults without diabetes, with a BMI of 30+ or 27-30 with an obesity-related complication including hypertension, dyslipidaemia, cardiovascular disease or obstructive sleep apnoea and a history of at least one patient-reported unsuccessful dietary effort to lose body weight, who have tried unsuccessfully to lose weight with diet alone